Silo Pharma

Silo Pharma

Pharmaceuticals
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company’s primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.

$3.5M

Market Cap • 11/17/2026

2010

(16 years)

Founded

2012

(14 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

0,4

P/S

98,1

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

3,9

EPS

—

Market Cap

Market Cap

3,5M

EV

-4,8M

EV/Revenue

-133,8

EV/EBITDA

1,1

EV/EBIT

1,1

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

0%

Total Yield

0%

Payout

0%

Retained Earnings

-22,3M

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

6037,9%

Capex/Revenue

0%

Capex/D&A

0%

Capex/OCF

0%

SBC/OCF

—

% PPE

0%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Revenue 5Y

-6,6%

CAGR Op. Income 5Y

52,4%

CAGR OCF 5Y

2,3%

Leverage

N.D./EBITDA

1,9

Debt/Equity

0%

Current Ratio

24,4

Quick Ratio

23,8

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium